Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.

Honvo G, Reginster JY, Rannou F, Rygaert X, Geerinck A, Rabenda V, McAlindon T, Charles A, Fuggle N, Cooper C, Curtis E, Arden N, Avouac B, Bruyère O.

Drugs Aging. 2019 Apr;36(Suppl 1):101-127. doi: 10.1007/s40266-019-00657-w.

2.

Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.

Honvo G, Reginster JY, Rabenda V, Geerinck A, Mkinsi O, Charles A, Rizzoli R, Cooper C, Avouac B, Bruyère O.

Drugs Aging. 2019 Apr;36(Suppl 1):65-99. doi: 10.1007/s40266-019-00662-z.

3.

Safety of Paracetamol in Osteoarthritis: What Does the Literature Say?

Conaghan PG, Arden N, Avouac B, Migliore A, Rizzoli R.

Drugs Aging. 2019 Apr;36(Suppl 1):7-14. doi: 10.1007/s40266-019-00658-9. Review.

4.

Clinical superiority of an innovative two-component compression system versus four-component compression system in treatment of active venous leg ulcers: A randomized trial.

Gillet JL, Guex JJ, Allaert FA, Avouac B, Leger P, Blaise S, Marchand A, Maillard H, Simon M, Amor CB, Pasqualini M.

Phlebology. 2019 Mar 5:268355519833523. doi: 10.1177/0268355519833523. [Epub ahead of print]

PMID:
30836836
5.

Effect of unloading brace treatment on pain and function in patients with symptomatic knee osteoarthritis: the ROTOR randomized clinical trial.

Thoumie P, Marty M, Avouac B, Pallez A, Vaumousse A, Pipet LPT, Monroche A, Graveleau N, Bonnin A, Amor CB, Coudeyre E.

Sci Rep. 2018 Jul 12;8(1):10519. doi: 10.1038/s41598-018-28782-3.

6.

Effect of an Institutional Medication Adherence Program for Long-Acting Injectable Risperidone on Adherence and Psychiatric Hospitalizations: Evidence from a Prospective Cohort Study.

Jalbert JJ, Rossignol M, Astruc B, Baylé F, Nordon C, Avouac B, Rouillon F, Abenhaim L, Grimaldi-Bensouda L.

J Popul Ther Clin Pharmacol. 2017 May 30;24(2):e61-e70. doi: 10.22374/1710-6222.24.2.7.

PMID:
28594483
7.

Homeopathic medical practice for anxiety and depression in primary care: the EPI3 cohort study.

Grimaldi-Bensouda L, Abenhaim L, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Begaud B; EPI3-LA-SER group.

BMC Complement Altern Med. 2016 May 4;16:125. doi: 10.1186/s12906-016-1104-2.

8.

Utilization of psychotropic drugs by patients consulting for sleeping disorders in homeopathic and conventional primary care settings: the EPI3 cohort study.

Grimaldi-Bensouda L, Abenhaim L, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Begaud B; EPI3-LA-SER Group.

Homeopathy. 2015 Jul;104(3):170-5. doi: 10.1016/j.homp.2015.05.002. Epub 2015 Jun 10.

PMID:
26143449
9.

Post-approval studies in France, challenges facing medical devices.

Levesque K, Coqueblin C, Guillot B; participants of round table n3 of Giens XXIX : Aubourg Lucie 4 Avouac Bernard 5 Carbonneil Cédric 6, Aubourg L, Avouac B, Carbonneil C, Cucherat M, Descamps-Mandine P, Hanoka S, Goldberg M, Josseran A, Parquin F, Pitel S, Ratignier C, Sechoy O, Szwarcenstein K, Tanti A, Teiger E, Thevenet N.

Therapie. 2014 Jul-Aug;69(4):303-21. doi: 10.2515/therapie/2014051. Epub 2014 Aug 12. English, French.

PMID:
25230354
10.

Les études post-inscriptions en France, quels enjeux pour les dispositifs médicaux.

Levesque K, Coqueblin C, Guillot B; et les participants à la table ronde N°3 de Giens XXIX, Aubourg L, Avouac B, Carbonneil C, Cucherat M, Descamps-Mandine P, Hanoka S, Goldberg M, Josseran A, Parquin F, Pitel S, Ratignier C, Sechoy O, Szwarcenstein K, Tanti A, Teiger E, Thevenet N.

Therapie. 2014 Jul-Aug;69(4):303-12. doi: 10.2515/therapie/2014047. French. No abstract available.

PMID:
27393225
11.

Management of upper respiratory tract infections by different medical practices, including homeopathy, and consumption of antibiotics in primary care: the EPI3 cohort study in France 2007-2008.

Grimaldi-Bensouda L, Bégaud B, Rossignol M, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Abenhaim L, Guillemot D.

PLoS One. 2014 Mar 19;9(3):e89990. doi: 10.1371/journal.pone.0089990. eCollection 2014.

12.

[Influenza, influenza-like illness: from theory to practice].

Carrat F, Avouac B, Cedraschi C, Duru G, Greppo G, Libourel V, Vancells J, Vétel JM.

Presse Med. 2014 Mar;43(3):240-6. doi: 10.1016/j.lpm.2013.09.004. Epub 2014 Jan 17. French.

PMID:
24440768
13.

Characteristics of patients consulting their regular primary care physician according to their prescribing preferences for homeopathy and complementary medicine.

Lert F, Grimaldi-Bensouda L, Rouillon F, Massol J, Guillemot D, Avouac B, Duru G, Magnier AM, Rossignol M, Abenhaim L, Begaud B; EPI3-LA-SER Group.

Homeopathy. 2014 Jan;103(1):51-7. doi: 10.1016/j.homp.2013.09.001.

PMID:
24439455
14.

Characterization of knee osteoarthritis in Latin America. A comparative analysis of clinical and health care utilization in Argentina, Brazil, and Mexico.

Burgos-Vargas R, Cardiel MH, Loyola-Sánchez A, De Abreu MM, Pons-Estel BA, Rossignol M, Avouac B, Ferraz MB, Halhol H.

Reumatol Clin. 2014 May-Jun;10(3):152-9. doi: 10.1016/j.reuma.2013.07.013. Epub 2013 Nov 26.

15.

Who seeks primary care for sleep, anxiety and depressive disorders from physicians prescribing homeopathic and other complementary medicine? Results from the EPI3 population survey.

Grimaldi-Bensouda L, Engel P, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Abenhaim L, Begaud B; EPI3-LA-SER group.

BMJ Open. 2012 Nov 22;2(6). pii: e001498. doi: 10.1136/bmjopen-2012-001498. Print 2012.

16.

Impact of physician preferences for homeopathic or conventional medicines on patients with musculoskeletal disorders: results from the EPI3-MSD cohort.

Rossignol M, Begaud B, Engel P, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L; EPI3-LA-SER group.

Pharmacoepidemiol Drug Saf. 2012 Oct;21(10):1093-101. doi: 10.1002/pds.3316. Epub 2012 Jul 11.

PMID:
22782803
17.

Health claims assessment in the field of joint and cartilage: a consensus viewpoint of the Group for the Respect of Ethics and Excellence in Science.

Bruyère O, Avouac B, Richette P, Maheu E, Bruel P, Coxam V, Guillou GB, Lugrin AE, Merceron C, Pauquai T, Rannou F, Ythier-Moury P, Tsouderos Y, Urban N, Rovati L, Guicheux J, Reginster JY.

Curr Med Res Opin. 2012 Apr;28(4):611-6. doi: 10.1185/03007995.2012.674934. Epub 2012 Mar 21. Review.

PMID:
22404901
18.

Benchmarking the burden of 100 diseases: results of a nationwide representative survey within general practices.

Grimaldi-Bensouda L, Begaud B, Lert F, Rouillon F, Massol J, Guillemot D, Avouac B, Duru G, Magnier AM, Rossignol M, Abenhaim L; EPI3-LA-SER Group.

BMJ Open. 2011 Nov 14;1(2):e000215. doi: 10.1136/bmjopen-2011-000215. Print 2011.

19.

Benchmarking clinical management of spinal and non-spinal disorders using quality of life: results from the EPI3-LASER survey in primary care.

Rossignol M, Begaud B, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L.

Eur Spine J. 2011 Dec;20(12):2210-6. doi: 10.1007/s00586-011-1780-z. Epub 2011 Apr 13.

20.

Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).

Bruyère O, Rizzoli R, Coxam V, Avouac B, Chevalier T, Fabien-Soulé V, Kanis JA, Kaufman JM, Tsouderos Y, Reginster JY.

Osteoporos Int. 2012 Jan;23(1):193-9. doi: 10.1007/s00198-011-1561-x. Epub 2011 Feb 25.

21.

Who seeks primary care for musculoskeletal disorders (MSDs) with physicians prescribing homeopathic and other complementary medicine? Results from the EPI3-LASER survey in France.

Rossignol M, Bégaud B, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L.

BMC Musculoskelet Disord. 2011 Jan 19;12:21. doi: 10.1186/1471-2474-12-21.

22.

Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Durez P, Flamion B, Laslop A, Miossec P, Reiter S, Reginster JY; Task Force of the Group for the Respect of Ethics and Excellence in Science.

Rheumatology (Oxford). 2011 Oct;50(10):1732-6. doi: 10.1093/rheumatology/keq413. Epub 2011 Jan 17. No abstract available.

PMID:
21242246
23.

Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.

Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B.

J Rheumatol. 2011 May;38(5):835-45. doi: 10.3899/jrheum.100665. Epub 2011 Jan 15.

24.

Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Dere WH, Durez P, Matucci-Cerinic M, Flamion B, Laslop A, Lekkerkerker FJ, Miossec P, Mitlak BH, Ormarsdóttir S, Paolozzi L, Rao R, Reiter S, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES).

Curr Med Res Opin. 2011 Feb;27(2):315-25. doi: 10.1185/03007995.2010.542135. Epub 2010 Dec 9.

PMID:
21142618
25.

Management recommendations for knee osteoarthritis: how usable are they?

Poitras S, Rossignol M, Avouac J, Avouac B, Cedraschi C, Nordin M, Rousseaux C, Rozenberg S, Savarieau B, Thoumie P, Valat JP, Vignon E, Hilliquin P.

Joint Bone Spine. 2010 Oct;77(5):458-65. doi: 10.1016/j.jbspin.2010.08.001. Epub 2010 Sep 18.

PMID:
20851659
26.

[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?].

Chaussade S, Avouac B, Vicaut E.

Presse Med. 2006 Sep;35 Suppl 1:61-8. doi: 10.1016/S0755-4982(06)74942-9. French.

PMID:
17870555
27.

A critical appraisal of guidelines for the management of knee osteoarthritis using Appraisal of Guidelines Research and Evaluation criteria.

Poitras S, Avouac J, Rossignol M, Avouac B, Cedraschi C, Nordin M, Rousseaux C, Rozenberg S, Savarieau B, Thoumie P, Valat JP, Vignon E, Hilliquin P.

Arthritis Res Ther. 2007;9(6):R126. Review.

28.

A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France.

Cotté FE, Cortet B, Lafuma A, Avouac B, Hasnaoui AE, Fardellone P, Pouchain D, Roux C, Gaudin AF.

Joint Bone Spine. 2008 Mar;75(2):201-8. Epub 2007 Aug 31. Erratum in: Joint Bone Spine. 2008 Mar;75(2):250-1.

PMID:
17988921
29.

Characterisation of patients with postmenopausal osteoporosis in French primary healthcare.

Blotman F, Cortet B, Hilliquin P, Avouac B, Allaert FA, Pouchain D, Gaudin AF, Cotté FE, El Hasnaoui A.

Drugs Aging. 2007;24(7):603-14.

PMID:
17658910
30.

[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?].

Chaussade S, Avouac B, Vicaut E.

Presse Med. 2006 Sep;35(9 Spec No 1):1S61-8. Review. French.

PMID:
17078597
31.

Assessing chronic pain in general practice: are guidelines relevant? A cluster randomized controlled trial.

Huas D, Pouchain D, Gay B, Avouac B, Bouvenot G, French College Of Teachers In General Practice.

Eur J Gen Pract. 2006;12(2):52-7.

PMID:
16945877
32.

Osteoarthritis of the knee and hip and activity: a systematic international review and synthesis (OASIS).

Vignon E, Valat JP, Rossignol M, Avouac B, Rozenberg S, Thoumie P, Avouac J, Nordin M, Hilliquin P.

Joint Bone Spine. 2006 Jul;73(4):442-55. Epub 2006 May 6. Review.

PMID:
16777458
33.

Primary osteoarthritis of hip, knee, and hand in relation to occupational exposure.

Rossignol M, Leclerc A, Allaert FA, Rozenberg S, Valat JP, Avouac B, Coste P, Litvak E, Hilliquin P.

Occup Environ Med. 2005 Nov;62(11):772-7.

34.

Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.

Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B.

Osteoporos Int. 2006 Jan;17(1):1-7. Epub 2005 Aug 10.

PMID:
16091835
35.

Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.

Abadie EC, Devogealer JP, Ringe JD, Ethgen DJ, Bouvenot GM, Kreutz G, Laslop A, Orloff JJ, Vanderauwera PM, Delmas PD, Dere WH, Branco J, Altman RD, Avouac BP, Menkes CJ, Vanhaelst L, Mitlak BH, Tsouderos Y, Reginster JY.

Semin Arthritis Rheum. 2005 Aug;35(1):1-4. Review.

PMID:
16084217
36.

Measuring the contribution of pharmacological treatment to advice to stay active in patients with subacute low-back pain: a randomised controlled trial.

Rossignol M, Allaert FA, Rozenberg S, Valat JP, Avouac B, Peres G, Le Teuff G, Bannwarth B.

Pharmacoepidemiol Drug Saf. 2005 Dec;14(12):861-7.

PMID:
15991263
37.

A randomized, double-blind, placebo controlled triphosphate in study of oral adenosine subacute low back pain.

Bannwarth B, Allaert FA, Avouac B, Rossignol M, Rozenberg S, Valat JP.

J Rheumatol. 2005 Jun;32(6):1114-7.

PMID:
15940776
38.

Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis.

Altman RD, Abadie E, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Menkes CJ, Pavelka K, Van De Putte L, Vanhaelst L, Reginster JY; Group for Respect of Excellence and Ethics in Science (GREES).

Osteoarthritis Cartilage. 2005 Jan;13(1):13-9. Review.

39.

Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.

Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY; Group for the Respect of Excellence and Ethics in Science.

Osteoarthritis Cartilage. 2004 Apr;12(4):263-8. Review.

40.

[Justification and indications for coxib therapy combined with gastro-protective agents].

Bertin P, Avouac B.

Presse Med. 2003 Nov 22;32(37 Pt 2):S44-7. Review. French.

PMID:
14763354
41.

[Prescription of NSAIDs in patients treatment with platelet inhibitors or anticoagulants].

Avouac B, Combe B, Darné B.

Presse Med. 2003 Nov 22;32(37 Pt 2):S38-43. Review. French.

PMID:
14763353
42.

Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain.

Devogelaer JP, Dreiser RL, Abadie E, Avouac B, Bouvenot G, Carbonell Abello J, Kaufman JM, Koes BW, Laslop A, Lemmel E, Richy F, Rozenberg S, Tavares V, Valat JP, Reginster JY.

Clin Exp Rheumatol. 2003 Nov-Dec;21(6):691-4. Review.

PMID:
14740445
43.

[Guidelines for the development of anti-osteoporosis medications].

Avouac B.

Therapie. 2003 Sep-Oct;58(5):421-4. Review. French.

PMID:
14682190
44.

Primary osteoarthritis and occupations: a national cross sectional survey of 10 412 symptomatic patients.

Rossignol M, Leclerc A, Hilliquin P, Allaert FA, Rozenberg S, Valat JP, Avouac B, Coste P, Savarieau B, Fautrel B.

Occup Environ Med. 2003 Nov;60(11):882-6.

45.
46.

[Current therapeutic possibilities in the treatment of arthrosis].

Avouac B.

Rev Prat. 2002 Mar 1;52(5 Suppl):S7-10. Review. French. No abstract available.

PMID:
11949495
47.

Points to consider for the development of new indications for hormone replacement therapies and estrogen-like molecules. Department of Urogynaecology, King's College Hospital, London.

Stevenson JC, Gaspard U, Avouac B, Bricaire C, Cardozo L, Collins P, Devogelaer JP, Dören M, Gennari C, Kaufman JM, Kuttenn F, Ringe JD, Scarafiotti C, Vanhaelst L, Zichella L, Ziegler R, Reginster JY.

Climacteric. 1998 Mar;1(1):12-7. Review. No abstract available.

PMID:
11913406
48.

The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis.

Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY; Group for the Respect of Ethics and Excellence in Science (GREES).

Osteoporos Int. 2002 Jan;13(1):1-5. Review.

PMID:
11878450
49.

[Current medical possibilities in the treatment of arthrosis].

Avouac B.

Presse Med. 2002 Jan 12;31(1 Pt 2):5-6. French.

PMID:
11826590
50.

Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers.

Vignon E, Garnero P, Delmas P, Avouac B, Bettica P, Boers M, Ehrich E, MacKillop N, Rovati L, Serni U, Spector T, Reginster JY; Respect of Ethics and Excellence in Science (GREES): Osteoarthritis Section.

Osteoarthritis Cartilage. 2001 May;9(4):289-93. No abstract available.

Supplemental Content

Loading ...
Support Center